Veru Inc. (VERU), a late clinical stage biopharmaceutical company, Wednesday announced a 1-for-10 reverse stock split, effective August 8.
This action is primarily to regain compliance with the Nasdaq $1.00 minimum bid price requirement.
For comments and feedback: editorial@rttnews.com